Ritter Pharmaceuticals Inc (RTTR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ritter Pharmaceuticals Inc (RTTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8138
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ritter Pharmaceuticals Inc (Ritter) is a developer of therapeutic products for gastrointestinal diseases. The company’s lead product includes RP-G28, which is developed stimulate the growth of lactose-metabolizing bacteria in the colon to assist in digesting process. Its product is under the development for the treatment of lactose intolerance. The company conducts research and development for developing product, which is used for treating various therapeutic areas such as gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. Ritter is headquartered in Los Angeles, California, the US.

Ritter Pharmaceuticals Inc (RTTR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Ritter Pharma Raises US$5.4 Million In Venture Financing 10
Ritter Pharma Raises US$0.53 Million In Venture Financing 11
Partnerships 12
Ritter Pharma Enters into Agreement with University of British Columbia 12
Ritter Pharma Enters into Agreement with University of Nebraska 13
Equity Offering 14
Ritter Pharma Raises USD23 Million in Public Offering of Units 14
Ritter Pharma Files Registration Statement to Raise up to USD10 Million in Public Offering of Units 16
Ritter Pharma to Raise Funds through Public Offering of Shares 17
Ritter Pharma to Raise up to USD8.4 Million in Public offering of Shares 18
Ritter Pharma Raises USD3 Million in Private Placement of Shares 19
Ritter Pharma Raises USD5 Million in Public Offering of Shares 20
Ritter Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 21
Ritter Pharma Raises USD20 Million in IPO 22
Ritter Pharma Raises Funds through Third and Final Trache of Private Placement of Share and Warrants 24
Ritter Pharma Raises USD2.4 Million in Second Trache of Private Placement of Share and Warrants 25
Ritter Pharma Raises USD1 Million in First Trache of Private Placement of Share and Warrants 26
Ritter Pharmaceuticals Inc – Key Competitors 27
Ritter Pharmaceuticals Inc – Key Employees 28
Ritter Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 14, 2018: Ritter Pharmaceuticals reports financial results for the three and six months ended June 30, 2018 and recent progress 30
May 15, 2018: Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates 31
Mar 19, 2018: Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 32
Oct 31, 2017: Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 34
Aug 07, 2017: Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 35
May 09, 2017: Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates 36
Feb 27, 2017: Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 38
Corporate Communications 39
Feb 20, 2018: Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, M.D., to Medical Advisory Board 39
Oct 10, 2017: Ritter Pharmaceuticals Announces Management Change 40
Jan 17, 2017: Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ritter Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ritter Pharma Raises US$5.4 Million In Venture Financing 11
Ritter Pharma Raises US$0.53 Million In Venture Financing 12
Ritter Pharma Enters into Agreement with University of British Columbia 13
Ritter Pharma Enters into Agreement with University of Nebraska 14
Ritter Pharma Raises USD23 Million in Public Offering of Units 15
Ritter Pharma Files Registration Statement to Raise up to USD10 Million in Public Offering of Units 17
Ritter Pharma to Raise Funds through Public Offering of Shares 18
Ritter Pharma to Raise up to USD8.4 Million in Public offering of Shares 19
Ritter Pharma Raises USD3 Million in Private Placement of Shares 20
Ritter Pharma Raises USD5 Million in Public Offering of Shares 21
Ritter Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 22
Ritter Pharma Raises USD20 Million in IPO 23
Ritter Pharma Raises Funds through Third and Final Trache of Private Placement of Share and Warrants 25
Ritter Pharma Raises USD2.4 Million in Second Trache of Private Placement of Share and Warrants 26
Ritter Pharma Raises USD1 Million in First Trache of Private Placement of Share and Warrants 27
Ritter Pharmaceuticals Inc, Key Competitors 28
Ritter Pharmaceuticals Inc, Key Employees 29

List of Figures
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Ritter Pharmaceuticals Inc (RTTR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Metabolomic Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary Metabolomic Technologies Inc (MTI) is a biotechnology company that develops metabolomic-based diagnostic systems. The company's products comprise ColoDx, PolypDx, BreastDx, ProstateDx, CeliacDx, ColitisDx, CrohnsDx and other products. Its products develop advanced diagnostic tests for gastro …
  • Vestel Elektronik Sanayi Ve Ticaret AS:企業の戦略・SWOT・財務分析
    Vestel Elektronik Sanayi Ve Ticaret AS - Strategy, SWOT and Corporate Finance Report Summary Vestel Elektronik Sanayi Ve Ticaret AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Nidec Corporation:戦略・SWOT・企業財務分析
    Nidec Corporation - Strategy, SWOT and Corporate Finance Report Summary Nidec Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Aurinia Pharmaceuticals Inc (AUP):企業の財務・戦略的SWOT分析
    Summary Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals), formerly Isotechnika Pharma Inc, is a clinical stage biopharmaceutical company which develops and commercializes therapies for the treatment of diseases with high unmet medical need. Its pipeline products include Voclosporin, is an inves …
  • TriVascular Inc:製品パイプライン分析
    Summary TriVascular Inc (TriVascular), a subsidiary of Endologix Inc is a medical device company that researches, designs and manufactures technologies to provide optimal solutions for endovascular aortic repair. The company’s product comprise endovascular grafts and self-expanding stent grafts; ova …
  • Murata Manufacturing Co Ltd (6981):企業の財務・戦略的SWOT分析
    Murata Manufacturing Co Ltd (6981) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • New York Power Authority:発電所・企業SWOT分析
    New York Power Authority - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Enka Power:企業の戦略的SWOT分析
    Enka Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Sanford Health:製薬・医療:M&Aディール及び事業提携情報
    Summary Sanford Health (Sanford) is a healthcare service provider that offers medical services. The center provides medical services in the areas of allergy and immunology, acupuncture, adult trauma, airmed, anesthesiology, breast health, behavioral health, pediatric care, bladder health, bleeding d …
  • MetGen Oy:製薬・医療:M&Aディール及び事業提携情報
    Summary MetGen Oy (MetGen) is a manufacturer and distributor of enzymatic solutions. The company offers metzyme, an industrial and natural catalysts used for accelerating chemical reactions. Its enzymatic solutions find applications in various processes such as mechanical processes, lignocellulosic …
  • Illinois Tool Works Inc.:企業の戦略・SWOT・財務情報
    Illinois Tool Works Inc. - Strategy, SWOT and Corporate Finance Report Summary Illinois Tool Works Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Bial - Portela & Ca SA (BIAL) is a pharmaceutical company that discovers, develops and provides drugs for neurosciences and cardiovascular therapeutic areas. The company offers products such as anti-inflammatories, anti-diabetics, cardiovascular, anti-asthmatics, antibiotics, antidepressants …
  • Valeo Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Valeo Pharma Inc (Valeo Pharma), a subsidiary of Manitex Capital Inc, is a pharmaceutical company that offers healthcare solutions and specialty products. The company provides dermatology products such as drops, tablets, solutions, injections among others. It develops, licenses, and commerci …
  • Knights of Columbus:企業の戦略的SWOT分析
    Knights of Columbus - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Bank of Panhsin:企業の戦略・SWOT・財務情報
    Bank of Panhsin - Strategy, SWOT and Corporate Finance Report Summary Bank of Panhsin - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Maroc Telecom SA (IAM):企業の財務・戦略的SWOT分析
    Maroc Telecom SA (IAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • GlaxoSmithKline Plc:企業のM&A・事業提携・投資動向
    GlaxoSmithKline Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GlaxoSmithKline Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Western Area Power Administration:企業の戦略的SWOT分析
    Western Area Power Administration - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Bourbon SA (GBB)-石油・ガス分野:企業M&A・提携分析
    Summary Bourbon SA (Bourbon) is a provider of marine and subsea services to the oil and gas industry. The company’s services consist of transport and supply of offshore material, floating production, storage and offloading (FPSO) support, anchor handling, towage and offshore positioning, assistance, …
  • Dairygold Co-operative Society Ltd:企業の戦略的SWOT分析
    Dairygold Co-operative Society Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆